Patent ID: 9623079
Date: 2017-04-18
CPC Classifications: A61K,A61P,C07K,Y02A

Claim:
1. A method of treating a mammalian subject with cancer with a therapeutic dose of an anti-CD47 agent that blocks the interaction between CD47 and SIRPα, selected from: an antibody that binds to CD47; an antibody that binds to SIRPα; a soluble SIRPα-binding CD47 fragment; and a soluble CD47-binding SIRPα fragment or a combination thereof, for treatment of the cancer, the method comprising: (a) administering a sub-therapeutic dose of one of the anti-CD47 agents to the subject, wherein the sub-therapeutic dose is effective to increase production of reticulocytes; and (b) administering a therapeutically effective dose of at least one of the anti-CD47 agents to the subject, wherein step (b) is performed in a range from about 3 days to about 21 days after beginning step (a).